{"id":972887,"date":"2026-06-16T18:14:51","date_gmt":"2026-06-16T22:14:51","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx\/"},"modified":"2026-06-16T18:14:51","modified_gmt":"2026-06-16T22:14:51","slug":"elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx\/","title":{"rendered":"Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX)"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Elicio Therapeutics reported Q1 2026 results showing a widening net loss and zero revenue days before its lead clinical program failed — investors who bought ELTX lost 72.5% in a single session.<\/i>\n <\/p>\n

\n NEW YORK<\/span>, June 16, 2026<\/span> \/PRNewswire\/ — Elicio Therapeutics (NASDAQ: ELTX) investors lost approximately 72.53% of their investment value today after the Company disclosed that its Phase 2 AMPLIFY-7P study of ELI-002 7P failed to meet the primary disease-free survival endpoint in pancreatic cancer. On June 9, the Company reported Q1 2026 earnings showing zero revenue and a widening net loss driven by R&D spending. Six days later, shares collapsed. Shareholders who lost money on ELTX are encouraged to submit their information here<\/a>. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com<\/a> or by telephone at (888) SueWallSt.<\/p>\n

\n

\n \"SueWallSt.com\"\n <\/p>\n<\/p><\/div>\n

The Q1 2026 filing showed the Company generated no product revenue while reporting increased research and development expenses tied to the AMPLIFY-7P program. The Company’s cash position funded operations centered on ELI-002 7P as its lead pipeline candidate. On June 15, the 144-patient Phase 2 trial missed its pre-specified primary endpoint.<\/p>\n

Days before the trial data became public, B. Riley Securities had issued a Buy rating with a $27 price target on June 10-11. The stock closed at only $4.08 after the Phase 2 miss was disclosed on June 15.<\/p>\n

If you purchased Elicio Therapeutics shares and suffered a loss, click here to discuss your legal rights<\/a>. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com<\/a> or by telephone at (888) SueWallSt.<\/p>\n

SueWallSt — Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.<\/p>\n

Frequently Asked Questions About the ELTX Investigation<\/p>\n

\n Q: Who is eligible to participate in the ELTX investigation? <\/b>A: Investors who purchased ELTX stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses — not on whether you still hold the shares.<\/p>\n

\n Q: How much did ELTX stock drop? <\/b>A: Shares fell approximately 72.5% after the Company disclosed that its Phase 2 AMPLIFY-7P trial of ELI-002 7P failed to meet the primary disease-free survival endpoint. Investors who purchased shares at higher prices may be entitled to recovery.<\/p>\n

\n Q: Which statements are being investigated as potentially misleading? <\/b>A: The investigation concerns whether Elicio Therapeutics made materially false or misleading statements regarding the prospects of ELI-002 7P and the AMPLIFY-7P clinical program. When the Phase 2 results were disclosed, the stock price declined sharply.<\/p>\n

\n Q: What do ELTX investors need to do right now? <\/b>A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact SueWallSt for a free, no-obligation evaluation at jlevi@SueWallSt.com<\/a> or (888) SueWallSt. No immediate action is required to remain eligible to participate in the investigation.<\/p>\n

\n Q: What happens after I contact SueWallSt? <\/b>A: An attorney will review your trading history at no cost and provide an initial assessment of your potential recovery.<\/p>\n

\n Q: What if I already sold my ELTX shares — can I still recover losses? <\/b>A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought ELTX and sold at a loss may still participate in the investigation.<\/p>\n

\n Q: What does it cost me to participate? <\/b>A: Nothing. Securities investigations and any resulting actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.<\/p>\n

CONTACT:
SueWallSt
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@SueWallSt.com<\/a>
Tel: (888) SueWallSt
Fax: (212) 363-7171<\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx-302802175.html<\/a><\/p>\n

SOURCE SueWallSt.com<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire Elicio Therapeutics reported Q1 2026 results showing a widening net loss and zero revenue days before its lead clinical program failed — investors who bought ELTX lost 72.5% in a single session. NEW YORK, June 16, 2026 \/PRNewswire\/ — Elicio Therapeutics (NASDAQ: ELTX) investors lost approximately 72.53% of their investment value today after the Company disclosed that its Phase 2 AMPLIFY-7P study of ELI-002 7P failed to meet the primary disease-free survival endpoint in pancreatic cancer. On June 9, the Company reported Q1 2026 earnings showing zero revenue and a widening net loss driven by R&D spending. Six days later, shares collapsed. Shareholders who lost money on ELTX are encouraged to submit their information here. You may also … <\/p>\n

Continue reading “Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-972887","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nElicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Elicio Therapeutics reported Q1 2026 results showing a widening net loss and zero revenue days before its lead clinical program failed — investors who bought ELTX lost 72.5% in a single session. NEW YORK, June 16, 2026 \/PRNewswire\/ — Elicio Therapeutics (NASDAQ: ELTX) investors lost approximately 72.53% of their investment value today after the Company disclosed that its Phase 2 AMPLIFY-7P study of ELI-002 7P failed to meet the primary disease-free survival endpoint in pancreatic cancer. On June 9, the Company reported Q1 2026 earnings showing zero revenue and a widening net loss driven by R&D spending. Six days later, shares collapsed. Shareholders who lost money on ELTX are encouraged to submit their information here. You may also … Continue reading "Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-16T22:14:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mmx.prnewswire.com\/media\/MS1812443\/suewallst-logo-1_Logo.jpg?id=OA2720630\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX)\",\"datePublished\":\"2026-06-16T22:14:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx\\\/\"},\"wordCount\":608,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1812443\\\/suewallst-logo-1_Logo.jpg?id=OA2720630\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx\\\/\",\"name\":\"Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1812443\\\/suewallst-logo-1_Logo.jpg?id=OA2720630\",\"datePublished\":\"2026-06-16T22:14:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1812443\\\/suewallst-logo-1_Logo.jpg?id=OA2720630\",\"contentUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1812443\\\/suewallst-logo-1_Logo.jpg?id=OA2720630\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx\/","og_locale":"en_US","og_type":"article","og_title":"Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX) - Market Newsdesk","og_description":"PR Newswire Elicio Therapeutics reported Q1 2026 results showing a widening net loss and zero revenue days before its lead clinical program failed — investors who bought ELTX lost 72.5% in a single session. NEW YORK, June 16, 2026 \/PRNewswire\/ — Elicio Therapeutics (NASDAQ: ELTX) investors lost approximately 72.53% of their investment value today after the Company disclosed that its Phase 2 AMPLIFY-7P study of ELI-002 7P failed to meet the primary disease-free survival endpoint in pancreatic cancer. On June 9, the Company reported Q1 2026 earnings showing zero revenue and a widening net loss driven by R&D spending. Six days later, shares collapsed. Shareholders who lost money on ELTX are encouraged to submit their information here. You may also … Continue reading \"Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-16T22:14:51+00:00","og_image":[{"url":"https:\/\/mmx.prnewswire.com\/media\/MS1812443\/suewallst-logo-1_Logo.jpg?id=OA2720630","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX)","datePublished":"2026-06-16T22:14:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx\/"},"wordCount":608,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1812443\/suewallst-logo-1_Logo.jpg?id=OA2720630","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx\/","name":"Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1812443\/suewallst-logo-1_Logo.jpg?id=OA2720630","datePublished":"2026-06-16T22:14:51+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx\/#primaryimage","url":"https:\/\/mmx.prnewswire.com\/media\/MS1812443\/suewallst-logo-1_Logo.jpg?id=OA2720630","contentUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1812443\/suewallst-logo-1_Logo.jpg?id=OA2720630"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/elicio-therapeutics-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-elicio-therapeutics-eltx\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/972887","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=972887"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/972887\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=972887"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=972887"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=972887"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}